Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.67 EUR | +2.28% | +2.58% | +2.14% |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- With a P/E ratio at 11.62 for the current year and 9.01 for next year, earnings multiples are highly attractive compared with competitors.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.14% | 17.39B | A- | ||
+20.68% | 85.55B | C+ | ||
-29.31% | 70.07B | B- | ||
+9.65% | 29.06B | C+ | ||
-8.63% | 17.51B | B | ||
+0.39% | 15.38B | A- | ||
+6.47% | 13.4B | B- | ||
+68.23% | 12.42B | C+ | ||
+6.43% | 12.77B | A- | ||
+31.27% | 12.06B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FRE Stock
- Ratings Fresenius SE & Co. KGaA